Business Description
Interpace Biosciences Inc
NAICS : 541380
SIC : 8099
ISIN : US46062X2045
Description
Interpace Biosciences Inc is a fully integrated commercial company. It provides molecular diagnostics, bioinformatics and pathology services for evaluation of risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The company develops and commercializes genomic tests and related first line assays principally focused on early detection of patients with indeterminate biopsies and at high risk of cancer using the latest technology.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.31 | |||||
| Equity-to-Asset | -4.74 | |||||
| Debt-to-Equity | -0.18 | |||||
| Debt-to-EBITDA | 2.97 | |||||
| Interest Coverage | 3.75 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | -24.3 | |||||
| Beneish M-Score | -3.11 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 4.6 | |||||
| 3-Year Book Growth Rate | -25.5 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 54.05 | |||||
| 9-Day RSI | 50.67 | |||||
| 14-Day RSI | 51.99 | |||||
| 6-1 Month Momentum % | 66.67 | |||||
| 12-1 Month Momentum % | 36.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.59 | |||||
| Quick Ratio | 0.52 | |||||
| Cash Ratio | 0.2 | |||||
| Days Inventory | 35.31 | |||||
| Days Sales Outstanding | 58.82 | |||||
| Days Payable | 43.23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.4 | |||||
| Shareholder Yield % | 18.65 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 60.86 | |||||
| Operating Margin % | 9.08 | |||||
| Net Margin % | 4.55 | |||||
| FCF Margin % | 7.6 | |||||
| ROE % | Neg. Equity | |||||
| ROA % | 9.43 | |||||
| ROIC % | 41.93 | |||||
| ROC (Joel Greenblatt) % | 87.09 | |||||
| ROCE % | 336.79 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 4.59 | |||||
| PE Ratio without NRI | 3.95 | |||||
| Price-to-Owner-Earnings | 3.4 | |||||
| PS Ratio | 0.2 | |||||
| Price-to-Free-Cash-Flow | 2.71 | |||||
| Price-to-Operating-Cash-Flow | 2.38 | |||||
| EV-to-EBIT | 5.87 | |||||
| EV-to-EBITDA | 3.75 | |||||
| EV-to-Revenue | 0.45 | |||||
| EV-to-Forward-Revenue | 0.44 | |||||
| EV-to-FCF | 5.81 | |||||
| Earnings Yield (Greenblatt) % | 17.04 | |||||
| FCF Yield % | 36.78 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers